Biocryst Pharmaceuticals (BCRX) EBITDA (2010 - 2026)

Biocryst Pharmaceuticals has reported EBITDA for 17 years, with the latest figure at -$722.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 297309.05% year-over-year to -$722.2 million; the trailing twelve-month figure through Mar 2026 stood at -$459.5 million (down 765.17% YoY), and the FY2025 full-year result was $263.0 million, up 394.5% from the prior year.
• EBITDA for Q1 2026 stood at -$722.2 million, down from $244.7 million in the prior quarter.
• The five-year high for EBITDA was $244.7 million in Q4 2025, with the low at -$722.2 million in Q1 2026.
• Historically, EBITDA has averaged -$60.1 million across 5 years, with a median of -$36.0 million in 2023.
• Annual changes were most pronounced in 2025 — EBITDA jumped 968.9% — and 2026, when it sank 297309.05%.
• Biocryst Pharmaceuticals' EBITDA stood at -$71.4 million in 2022, then grew by 14.31% to -$61.2 million in 2023, then surged by 53.97% to -$28.2 million in 2024, then jumped by 968.9% to $244.7 million in 2025, then sank by 395.09% to -$722.2 million in 2026.
• The last three EBITDA figures came in at -$722.2 million (Q1 2026), $244.7 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.